Myasthenia Gravis Treatment Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2030

Description

Persistence Market Research has recently published an in-depth analysis of the global myasthenia gravis treatment market, presenting a comprehensive understanding of key market dynamics, growth drivers, challenges, and emerging trends. Exclusive data and statistics are presented to forecast the market's growth trajectory from 2023 to 2030.

The global myasthenia gravis treatment market is forecasted to expand at a CAGR of 8.5% and thereby increase from a value of US$2.3Bn in 2023 to US$4.1Bn by the end of 2030.

Key Insights:

Myasthenia Gravis Treatment Market Size (2023E): US$2.3 Billion
Projected Market Value (2030F): US$4.1 Billion
Global Market Growth Rate (CAGR 2023 to 2030): 8.5%
Historical Market Growth Rate (CAGR 2018 to 2022): 5.7%

Market Scope:

Myasthenia Gravis (MG) treatment aims to ease neuromuscular issues caused by the autoimmune disorder. It primarily focuses on enhancing nerve-muscle communication using acetylcholinesterase inhibitors and managing the immune response with drugs like corticosteroids. Emerging therapies, including monoclonal antibodies, show promise. With MG becoming more prevalent, research is intensifying, leading to targeted treatments and personalized medicine. Collaboration between pharmaceutical companies and research institutions is driving innovation to improve treatment effectiveness and accessibility for MG patients.

Market Growth Drivers:

The myasthenia gravis treatment market is thriving due to advancements in immunotherapies, particularly monoclonal antibodies targeting specific immune components. These therapies aim to modulate immune responses, improving outcomes for patients by reducing the impact of autoantibodies on neuromuscular junctions. The approval and integration of innovative agents like eculizumab and rituximab mark a transformative shift in treatment paradigms, offering more precise management. Additionally, the rising incidence of the disease, coupled with increased awareness and improved diagnostics, drives demand for effective treatments. The growing recognition of myasthenia gravis prompts proactive management strategies, fostering market growth as pharmaceutical companies and healthcare providers collaborate to meet evolving patient needs.

Market Restraints:

Despite the promising growth outlook, the myasthenia gravis treatment market faces challenges such as high treatment costs, limited access to healthcare in developing regions, and potential side effects associated with immunomodulatory therapies. Additionally, regulatory hurdles and stringent approval processes for new drugs pose challenges for market expansion.

Market Opportunities:

Personalized therapies present a lucrative revenue opportunity in the Myasthenia Gravis Treatment Market. Tailoring treatments based on individual patient profiles enhances efficacy and reduces adverse effects. Precision medicine allows for targeted therapies addressing specific disease manifestations. Companies investing in personalized treatment approaches can differentiate themselves and improve patient outcomes, ultimately driving revenue. Additionally, expanding the therapeutic landscape beyond traditional treatments unlocks untapped market potential. Novel modalities like targeted biologics and gene therapies offer more effective interventions, catering to evolving patient needs and creating new revenue streams in the competitive market.

Key Questions Answered in the Report:

What are the current trends and future prospects in the global myasthenia gravis treatment market?
What are the key factors influencing market growth and adoption of treatment modalities?
Which regions are poised to lead market growth, and what factors contribute to their dominance?
Who are the key players driving innovation and market expansion in the myasthenia gravis treatment segment?
What strategies are market players adopting to overcome challenges and gain a competitive edge?

Competitive Landscape:

Leading organizations like Alexion Pharmaceutical Inc., Grifols SA, Avadel Pharmaceuticals plc., Novartis AG, and Pfizer Inc. are driving the Myasthenia Gravis Treatment Market. Competitive intelligence is vital, involving understanding competitors' research, clinical trial progress, and market positioning. Analyzing successes and challenges in introducing innovative treatments like monoclonal antibodies helps anticipate trends. Robust competitive intelligence empowers stakeholders to respond proactively to market shifts. Crafting a successful strategy involves diversifying treatment portfolios, collaborating with research institutions, and emphasizing personalized medicine.

Market Segmentation:

The myasthenia gravis treatment market encompasses a diverse range of therapeutic approaches tailored to individual patient needs. Market segmentation includes variations in treatment modalities, patient demographics, and geographical regions, allowing for targeted interventions and personalized healthcare delivery.

By Drug Class:

Cholinesterase Inhibitors
Corticosteroids
Immunosuppressants
IVIg
Monoclonal Antibodies

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region:

North America
Europe
East Asia
South Asia & Oceania
Latin America
Middle East & Africa

Product Code: PMRREP33757

1. Executive Summary

1.1. Global Myasthenia Gravis Treatment Market Snapshot, 2023 and 2030
1.2. Market Opportunity Assessment, 2023 - 2030, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations

2. Market Overview

2.1. Market Scope and Definition
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Challenges
- 2.2.5. Key Trends
2.3. Drug Class Lifecycle Analysis
2.4. Myasthenia Gravis Treatment Market: Value Chain
- 2.4.1. List of Raw Material Supplier
- 2.4.2. List of Manufacturers
- 2.4.3. List of Distributors
- 2.4.4. List of Applications
- 2.4.5. Profitability Analysis
2.5. Porter Five Force's Analysis
2.6. Geopolitical Tensions: Market Impact
2.7. Macro-Economic Factors
- 2.7.1. Global Sectorial Outlook
- 2.7.2. Global GDP Growth Outlook
- 2.7.3. Global Parent Market Overview
2.8. Forecast Factors - Relevance and Impact
2.9. Regulatory and Technology Landscape

3. Global Myasthenia Gravis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

3.1. Key Highlights
- 3.1.1. Market Volume (Units) Projections
- 3.1.2. Market Size and Y-o-Y Growth
- 3.1.3. Absolute $ Opportunity
3.2. Market Size (US$ Mn) Analysis and Forecast
- 3.2.1. Historical Market Size Analysis, 2013-2016
- 3.2.2. Current Market Size Forecast, 2018-2026
3.3. Global Myasthenia Gravis Treatment Market Outlook: Drug Class
- 3.3.1. Introduction / Key Findings
- 3.3.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Drug Class, 2018 - 2022
- 3.3.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2023 - 2030
  - 3.3.3.1. Cholinesterase Inhibitors
  - 3.3.3.2. Corticosteroids
  - 3.3.3.3. Immunosuppressants
  - 3.3.3.4. IVIg
  - 3.3.3.5. Monoclonal
3.4. Market Attractiveness Analysis: Drug Class
3.5. Global Myasthenia Gravis Treatment Market Outlook: Distribution Channel
- 3.5.1. Introduction / Key Findings
- 3.5.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Distribution Channel, 2018 - 2022
- 3.5.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
  - 3.5.3.1. Hospital Pharmacies
  - 3.5.3.2. Retail Pharmacies
  - 3.5.3.3. Online Pharmacies
3.6. Market Attractiveness Analysis: Distribution Channel

4. Global Myasthenia Gravis Treatment Market Outlook: Region

4.1. Key Highlights
4.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Region, 2018 - 2022
4.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Region, 2023 - 2030
- 4.3.1. North America
- 4.3.2. Europe
- 4.3.3. East Asia
- 4.3.4. South Asia & Pacific
- 4.3.5. Latin America
- 4.3.6. Middle East & Africa (MEA)
4.4. Market Attractiveness Analysis: Region

5. North America Myasthenia Gravis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

5.1. Key Highlights
5.2. Pricing Analysis
5.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 5.3.1. By Country
- 5.3.2. By Drug Class
- 5.3.3. By Distribution Channel
5.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 5.4.1. U.S.
- 5.4.2. Canada
5.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2023 - 2030
- 5.5.1. Cholinesterase Inhibitors
- 5.5.2. Corticosteroids
- 5.5.3. Immunosuppressants
- 5.5.4. IVIg
- 5.5.5. Monoclonal
5.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
- 5.6.1. Hospital Pharmacies
- 5.6.2. Retail Pharmacies
- 5.6.3. Online Pharmacies
5.7. Market Attractiveness Analysis

6. Europe Myasthenia Gravis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

6.1. Key Highlights
6.2. Pricing Analysis
6.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 6.3.1. By Country
- 6.3.2. By Drug Class
- 6.3.3. By Distribution Channel
6.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 6.4.1. Germany
- 6.4.2. France
- 6.4.3. U.K.
- 6.4.4. Italy
- 6.4.5. Spain
- 6.4.6. Russia
- 6.4.7. Turkey
- 6.4.8. Rest of Europe
6.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2023 - 2030
- 6.5.1. Cholinesterase Inhibitors
- 6.5.2. Corticosteroids
- 6.5.3. Immunosuppressants
- 6.5.4. IVIg
- 6.5.5. Monoclonal
6.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
- 6.6.1. Hospital Pharmacies
- 6.6.2. Retail Pharmacies
- 6.6.3. Online Pharmacies
6.7. Market Attractiveness Analysis

7. East Asia Myasthenia Gravis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

7.1. Key Highlights
7.2. Pricing Analysis
7.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 7.3.1. By Country
- 7.3.2. By Drug Class
- 7.3.3. By Distribution Channel
7.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 7.4.1. China
- 7.4.2. Japan
- 7.4.3. South Korea
7.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2023 - 2030
- 7.5.1. Cholinesterase Inhibitors
- 7.5.2. Corticosteroids
- 7.5.3. Immunosuppressants
- 7.5.4. IVIg
- 7.5.5. Monoclonal
7.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
- 7.6.1. Hospital Pharmacies
- 7.6.2. Retail Pharmacies
- 7.6.3. Online Pharmacies
7.7. Market Attractiveness Analysis

8. South Asia & Oceania Myasthenia Gravis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

8.1. Key Highlights
8.2. Pricing Analysis
8.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 8.3.1. By Country
- 8.3.2. By Drug Class
- 8.3.3. By Distribution Channel
8.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 8.4.1. India
- 8.4.2. Southeast Asia
- 8.4.3. ANZ
- 8.4.4. Rest of South Asia & Oceania
8.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2023 - 2030
- 8.5.1. Cholinesterase Inhibitors
- 8.5.2. Corticosteroids
- 8.5.3. Immunosuppressants
- 8.5.4. IVIg
- 8.5.5. Monoclonal
8.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
- 8.6.1. Hospital Pharmacies
- 8.6.2. Retail Pharmacies
- 8.6.3. Online Pharmacies
8.7. Market Attractiveness Analysis

9. Latin America Myasthenia Gravis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

9.1. Key Highlights
9.2. Pricing Analysis
9.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 9.3.1. By Country
- 9.3.2. By Drug Class
- 9.3.3. By Distribution Channel
9.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 9.4.1. Brazil
- 9.4.2. Mexico
- 9.4.3. Rest of Latin America
9.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2023 - 2030
- 9.5.1. Cholinesterase Inhibitors
- 9.5.2. Corticosteroids
- 9.5.3. Immunosuppressants
- 9.5.4. IVIg
- 9.5.5. Monoclonal
9.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
- 9.6.1. Hospital Pharmacies
- 9.6.2. Retail Pharmacies
- 9.6.3. Online Pharmacies
9.7. Market Attractiveness Analysis

10. Middle East & Africa Myasthenia Gravis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

10.1. Key Highlights
10.2. Pricing Analysis
10.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 10.3.1. By Country
- 10.3.2. By Drug Class
- 10.3.3. By Distribution Channel
10.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 10.4.1. GCC
- 10.4.2. Egypt
- 10.4.3. South Africa
- 10.4.4. Northern Africa
- 10.4.5. Rest of Middle East & Africa
10.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2023 - 2030
- 10.5.1. Cholinesterase Inhibitors
- 10.5.2. Corticosteroids
- 10.5.3. Immunosuppressants
- 10.5.4. IVIg
- 10.5.5. Monoclonal
10.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
- 10.6.1. Hospital Pharmacies
- 10.6.2. Retail Pharmacies
- 10.6.3. Online Pharmacies
10.7. Market Attractiveness Analysis

11. Competition Landscape

11.1. Market Share Analysis, 2022
11.2. Market Structure
- 11.2.1. Competition Intensity Mapping By Market
- 11.2.2. Competition Corticosteroids
- 11.2.3. Apparent Product Capacity
11.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 11.3.1. Alexion Pharmaceutical Inc.
  - 11.3.1.1. Overview
  - 11.3.1.2. Segments and Product
  - 11.3.1.3. Key Financials
  - 11.3.1.4. Market Developments
  - 11.3.1.5. Market Strategy
- 11.3.2. Grifols SA
  - 11.3.2.1. Overview
  - 11.3.2.2. Segments and Product
  - 11.3.2.3. Key Financials
  - 11.3.2.4. Market Developments
  - 11.3.2.5. Market Strategy
- 11.3.3. Avadel Pharmaceuticals plc.
  - 11.3.3.1. Overview
  - 11.3.3.2. Segments and Product
  - 11.3.3.3. Key Financials
  - 11.3.3.4. Market Developments
  - 11.3.3.5. Market Strategy
- 11.3.4. Novartis AG
  - 11.3.4.1. Overview
  - 11.3.4.2. Segments and Product
  - 11.3.4.3. Key Financials
  - 11.3.4.4. Market Developments
  - 11.3.4.5. Market Strategy
- 11.3.5. Pfizer; Inc.
  - 11.3.5.1. Overview
  - 11.3.5.2. Segments and Product
  - 11.3.5.3. Key Financials
  - 11.3.5.4. Market Developments
  - 11.3.5.5. Market Strategy
- 11.3.6. AbbVie Inc.
  - 11.3.6.1. Overview
  - 11.3.6.2. Segments and Product
  - 11.3.6.3. Key Financials
  - 11.3.6.4. Market Developments
  - 11.3.6.5. Market Strategy
- 11.3.7. F. Hoffmann-La Roche Ltd.
  - 11.3.7.1. Overview
  - 11.3.7.2. Segments and Product
  - 11.3.7.3. Key Financials
  - 11.3.7.4. Market Developments
  - 11.3.7.5. Market Strategy
- 11.3.8. GlaxoSmithKline plc
  - 11.3.8.1. Overview
  - 11.3.8.2. Segments and Product
  - 11.3.8.3. Key Financials
  - 11.3.8.4. Market Developments
  - 11.3.8.5. Market Strategy
- 11.3.9. Bausch Health Companies Inc.
  - 11.3.9.1. Overview
  - 11.3.9.2. Segments and Product
  - 11.3.9.3. Key Financials
  - 11.3.9.4. Market Developments
  - 11.3.9.5. Market Strategy
- 11.3.10. Shire plc.
  - 11.3.10.1. Overview
  - 11.3.10.2. Segments and Product
  - 11.3.10.3. Key Financials
  - 11.3.10.4. Market Developments
  - 11.3.10.5. Market Strategy

12. Appendix

12.1. Research Methodology
12.2. Research Assumptions
12.3. Acronyms and Abbreviations